Estados Unidos · Agencias y tiempo real · PR Newswire

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

Publicado por PR Newswire · Estados Unidos hace 4 h

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research,…

Leer el artículo completo en PR Newswire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

También te puede interesar

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Infinity Hires Meta Superintelligence Labs Chip Veteran and the CUDA Educator Who's Taught Two Million Engineers

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

Compartir

También te puede interesar

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Infinity Hires Meta Superintelligence Labs Chip Veteran and the CUDA Educator Who's Taught Two Million Engineers

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows